Sparrow Pharmaceuticals to Present New Clinical Pharmacology Data on SPI-62 at the Endocrine Society (ENDO) 2022 Annual Conference

Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, today announced that it will present new clinical pharmacology data at the Endocrine Society (ENDO) 2022 Annual Conference on its candidate, SPI-62, an HSD-1 inhibitor. Sparrow will present the data during an in-person poster session and a Rapid Fire e-Poster presentation. ENDO 2022 will take place June 11-14, 2022 in Atlanta, Georgia.

The poster presentation session and Rapid Fire e-Poster presentation details are summarized below:

ENDO 2022 Rapid Fire e-Poster Presentation

• Title: HPA Axis Modulation by a Potent Inhibitor Indicates 11b-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Is a Significant Contributor to Cortisol Levels
• E-Poster Number: RF21
• Presenting Authors: David A. Katz, Ph.D. and Mark Mortier, MS
• Rapid Session Date/Time: Sunday, June 12^th, 2022 from 1:06pm – 1:11pm ET in ENDOExpo, Pod 7

ENDO 2022 In-Person Poster Presentation

• Title: HPA Axis Modulation by a Potent Inhibitor Indicates 11b-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Is a Significant Contributor to Cortisol Levels
• Poster Number: PSAT100
• Presenting Authors: David A. Katz, Ph.D. and Mark Mortier, MS
• Rapid Session Date/Time: Sunday, June 12^th, 2022 from 1:00pm – 3:00pm ET in HallA1

To register and view the abstracts, visit ENDO’s website here.

To learn more about Sparrow Pharmaceuticals and its leadership team, visit the website at www.sparrowpharma.com.

About Sparrow Pharmaceuticals

Sparrow Pharmaceuticals was founded to spare patients the ravages of steroids. Leveraging underappreciated scientific insights into steroid biology, the company is working to provide better treatment options for serious disorders of hypercortisolism, and to revolutionize the treatment of autoimmune and inflammatory conditions. SPI-62, is an oral, small molecule, novel therapeutic treatment designed to target the source of active intracellular glucocorticoids in key tissues. SPI-47 is a fixed-dose-combination of SPI-62 and the glucocorticoid medicine prednisolone.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220614005176/en/